SLDB Stock Price, Solid Biosciences Inc Quote, Chart

Market Summary

USD8.95-0.35

Market Closed

-3.76%

SLDB Stock Price

View Fullscreen

SLDB RSI Chart

SLDB Valuation

Market Cap

343.5M

Price/Earnings (Trailing)

-3.81

Price/Sales (Trailing)

45.95

Price/Free Cashflow

-3.71

SLDB Price/Sales (Trailing)

SLDB Profitability

Return on Equity

-42.83%

Return on Assets

-36.29%

Free Cashflow Yield

-26.94%

SLDB Fundamentals

SLDB Revenue

Revenue (TTM)

8.1M

SLDB Earnings

Earnings (TTM)

-90.2M

Earnings Growth (Yr)

19.18%

Earnings Growth (Qtr)

-19.51%

Breaking Down SLDB Revenue

Last 7 days

-13.9%

Last 30 days

-10.4%

Last 90 days

-10.7%

Trailing 12 Months

47.9%

How does SLDB drawdown profile look like?

SLDB Financial Health

Current Ratio

14.94

SLDB Investor Care

Shares Dilution (1Y)

95.80%

Diluted EPS (TTM)

-3.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	12.2M	14.8M	11.2M	8.1M
2021	0	0	0	13.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Solid Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	ganot ilan	acquired	-	-	1,553	-
May 02, 2024	ganot ilan	sold	-4,772	10.33	-462	-
Apr 03, 2024	smith ian f	acquired	-	-	3,256	-
Jan 29, 2024	ganot ilan	sold	-1,110	7.99	-139	-
Jan 27, 2024	ganot ilan	acquired	-	-	388	-
Jan 27, 2024	ganot ilan	acquired	-	-	3,883	-
Jan 11, 2024	perceptive advisors llc	bought	18,861,200	5.53	3,410,710	-
Jan 11, 2024	koppel adam	acquired	5,000,000	5.53	904,160	-
Jan 11, 2024	bain capital life sciences investors, llc	acquired	5,000,000	5.53	904,160	-
Jan 11, 2024	ra capital management, l.p.	bought	5,000,000	5.53	904,160	-

Which funds bought or sold SLDB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	added	174	27,717,000	33,300,000	0.85%
May 16, 2024	JANE STREET GROUP, LLC	new	-	1,145,570	1,145,570	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	366,589	680,079	0.01%
May 15, 2024	Royal Bank of Canada	reduced	-97.84	-17,000	1,000	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	2,713,920	2,713,920	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	458,541	458,541	-%
May 15, 2024	JANUS HENDERSON GROUP PLC	new	-	23,934,700	23,934,700	0.01%
May 15, 2024	BARCLAYS PLC	unchanged	-	32,000	59,000	-%
May 15, 2024	RA CAPITAL MANAGEMENT, L.P.	added	26.39	36,644,100	57,681,500	0.73%
May 15, 2024	STATE STREET CORP	added	64.36	702,469	976,276	-%

Are Funds Buying or Selling SLDB?

Are funds buying SLDB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SLDB

No. of Funds

Unveiling Solid Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 07, 2024	adage capital partners gp, l.l.c.	7.25%	2,712,478	SC 13G
Jan 22, 2024	artal international s.c.a.	7.3%	2,717,538	SC 13G
Jan 12, 2024	flynn james e	6.08%	2,260,398	SC 13G
Jan 12, 2024	perceptive advisors llc	18.6%	6,925,028	SC 13D/A
Jan 12, 2024	bcls sb investco, lp	1.4%	528,660	SC 13D/A
Jan 11, 2024	ra capital management, l.p.	11.7%	4,348,828	SC 13D/A
Jan 10, 2024	bcls sb investco, lp	2.6%	528,660	SC 13D/A
Feb 13, 2023	suvretta capital management, llc	0%	0	SC 13G/A
Feb 13, 2023	k2 principal fund, l.p.	1.46%	284,871	SC 13G/A
Feb 10, 2023	ecor1 capital, llc	0%	0	SC 13G/A

Recent SEC filings of Solid Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	S-3/A	S-3/A
May 06, 2024	4	Insider Trading
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 12, 2024	PRE 14A	PRE 14A
Apr 05, 2024	4	Insider Trading
Mar 13, 2024	S-3	S-3
Mar 13, 2024	10-K	Annual Report

Peers (Alternatives to Solid Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Solid Biosciences Inc News

Latest updates

Solid Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-	-	-	6.00	2.00	3.00	4.00	4.00	3.00
Operating Expenses	63.6%	35.00	21.00	32.00	27.00	22.00	22.00	22.00	20.00
S&GA Expenses	6.9%	8.00	7.00	7.00	7.00	7.00	7.00	7.00	6.00
R&D Expenses	52.0%	21.00	14.00	23.00	20.00	15.00	14.00	16.00	14.00
Net Income	25.8%	-15.15	-20.41	-25.09	-25.33	-18.61	-17.98	-18.69	-16.90
Net Income Margin	-33.6%	-10.62*	-7.95*	-5.89*	-6.60*	-5.30*	-	-	-
Free Cashflow	-66.1%	-35.34	-21.27	-17.01	-27.37	-21.53	-18.66	-17.45	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	50.8%	249	165	185	205	230	260	184	208	208	232	249	266	285	171	41.00	58.00	74.00	103	131	96.00	120
Current Assets	65.1%	214	130	148	167	191	220	148	170	199	223	239	255	274	159	27.00	44.00	58.00	86.00	113	78.00	102
Cash Equivalents	61.3%	119	74.00	49.00	92.00	165	155	49.00	54.00	130	119	110	201	268	155	25.00	41.00	54.00	76.00	95.00	52.00	54.00
Net PPE	-3.5%	6.00	7.00	7.00	7.00	9.00	10.00	6.00	7.00	6.00	6.00	7.00	7.00	7.00	8.00	9.00	10.00	11.00	12.00	11.00	12.00	12.00
Liabilities	-1.3%	38.00	38.00	40.00	41.00	46.00	49.00	41.00	46.00	22.00	24.00	26.00	28.00	32.00	39.00	18.00	17.00	18.00	23.00	22.00	20.00	21.00
Current Liabilities	-1.2%	14.00	15.00	16.00	16.00	20.00	23.00	17.00	22.00	22.00	24.00	23.00	23.00	23.00	24.00	15.00	13.00	13.00	18.00	17.00	14.00	15.00
Shareholder's Equity	66.6%	211	126	144	164	184	212	143	162	186	208	223	238	253	132	22.00	41.00	56.00	80.00	109	76.00	99.00
Retained Earnings	-3.7%	-683	-658	-638	-617	-592	-562	-547	-527	-502	-476	-458	-440	-421	-404	-383	-361	-342	-316	-284	-255	-228
Additional Paid-In Capital	13.8%	894	785	783	781	777	774	691	689	688	685	681	678	674	537	405	403	399	396	393	332	328
Shares Outstanding	85.6%	38.00	20.00	20.00	20.00	20.00	20.00	8.00	8.00	8.00	7.00	7.00	7.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	52.00	-	-	-	46.00	-	-	-	272	-	-	-	73.00	-	-	-	101	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-21.0%	-25,200	-20,823	-17,897	-27,465	-27,995	-34,480	-20,429	-15,878	-27,190	-20,874	-18,424	-17,100	-21,366	1,307	-15,564	-13,068	-29,274	-21,245	-19,241	-26,301	-25,927
Share Based Compensation	-16.9%	1,611	1,938	1,625	1,944	2,118	1,587	1,524	1,814	2,612	3,415	3,416	3,635	2,907	2,518	2,764	3,243	3,104	3,404	3,392	3,911	3,500
Cashflow From Investing	-185.0%	-38,490	45,296	-24,635	-48,232	37,260	66,100	14,909	-59,595	37,743	30,176	-72,510	-48,717	-35.00	-60.00	-80.00	322	6,418	2,855	3,963	24,143	-6,445
Cashflow From Financing	21135.8%	107,241	505	-	-	-	74,737	-1.00	73.00	22.00	66.00	3.00	-238	135,154	-	-	-	-	-287	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SLDB Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 18,873	$ 24,631
General and administrative	7,989	7,399
Total operating expenses	26,862	32,030
Loss from operations	(26,862)	(32,030)
Other income, net:
Interest income	2,651	1,799
Interest expense	(95)	(121)
Other income, net	3	282
Total other income, net	2,559	1,960
Net loss	$ (24,303)	$ (30,070)
Net loss per share, basic	$ (0.64)	$ (1.54)
Net loss per share, diluted	$ (0.64)	$ (1.54)
Weighted average shares of common stock outstanding, basic	38,155,373	19,567,635
Weighted average shares of common stock outstanding, diluted	38,155,373	19,567,635

SLDB Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 117,574	$ 74,015
Available-for-sale securities	88,492	49,625
Prepaid expenses and other current assets	8,126	6,094
Total current assets	214,192	129,734
Operating lease, right-of-use assets	26,098	26,539
Property and equipment, net	6,391	6,624
Other non-current assets	175	209
Restricted cash	1,833	1,833
Total assets	248,689	164,939
Current liabilities:
Accounts payable	1,730	2,032
Accrued expenses	10,327	10,137
Operating lease liabilities	1,694	1,855
Finance lease liabilities	496	469
Other current liabilities	92	24
Total current liabilities	14,339	14,517
Operating lease liabilities, excluding current portion	22,526	22,707
Finance lease liabilities, excluding current portion	1,100	1,234
Total liabilities	37,965	38,458
Commitments and contingencies (Note 11)
Preferred stock, $0.001 par value - 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value - 60,000,000 shares authorized; 37,833,689 and 20,386,606 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	38	20
Additional paid-in capital	893,746	785,199
Accumulated other comprehensive (loss) income	(4)	15
Accumulated deficit	(683,056)	(658,753)
Total stockholders’ equity	210,724	126,481
Total liabilities and stockholders’ equity	$ 248,689	$ 164,939

About Solid Biosciences Inc

Solid Biosciences Inc., a life science company, engages in developing therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne); AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia; AVB-401, a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and other drugs for the treatment of undisclosed cardiac diseases. It also engages in developing platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

CEO	Mr. Alexander G. Cumbo
WEBSITE	solidbio.com
INDUSTRY	Biotechnology
EMPLOYEES	87

Solid Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Solid Biosciences Inc? What does SLDB stand for in stocks?

SLDB is the stock ticker symbol of Solid Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Solid Biosciences Inc (SLDB)?

As of Fri May 17 2024, market cap of Solid Biosciences Inc is 343.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SLDB stock?

You can check SLDB's fair value in chart for subscribers.

What is the fair value of SLDB stock?

You can check SLDB's fair value in chart for subscribers. The fair value of Solid Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Solid Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SLDB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Solid Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether SLDB is over valued or under valued. Whether Solid Biosciences Inc is cheap or expensive depends on the assumptions which impact Solid Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLDB.

What is Solid Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SLDB's PE ratio (Price to Earnings) is -3.81 and Price to Sales (PS) ratio is 45.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLDB PE ratio will change depending on the future growth rate expectations of investors.